Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
Avalon GloboCare (NASDAQ: ALBT) has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board to support the development of KetoAir™, a handheld breathalyzer for ketogenic health monitoring. Dr. Cavo, co-founder and CMO of Pounds Transformation, brings expertise in obesity medicine and bariatric care. KetoAir™ measures Breath Acetone Concentration (BrAce) as a biomarker for ketosis, offering a non-invasive alternative to blood and urine testing. The device aims to support weight management and conditions like diabetes by providing real-time feedback on ketosis levels.
Avalon GloboCare (NASDAQ: ALBT) ha nominato Dr. Charles Cavo nel suo Comitato Consultivo Scientifico e Clinico per sostenere lo sviluppo di KetoAir™, un'unità portatile per il monitoraggio della salute che utilizza il respiro. Il Dr. Cavo, co-fondatore e CMO di Pounds Transformation, porta con sé una vasta esperienza nella medicina dell'obesità e nella cura bariatrica. KetoAir™ misura la concentrazione di acetone nel respiro (BrAce) come biomarcatore della chetosi, offrendo un'alternativa non invasiva ai test del sangue e delle urine. Il dispositivo si propone di supportare la gestione del peso e condizioni come il diabete, fornendo feedback in tempo reale sui livelli di chetosi.
Avalon GloboCare (NASDAQ: ALBT) ha nombrado al Dr. Charles Cavo en su Junta Asesora Científica y Clínica para apoyar el desarrollo de KetoAir™, un analizador de aliento portátil para el monitoreo de la salud cetogénica. El Dr. Cavo, cofundador y CMO de Pounds Transformation, aporta experiencia en medicina de la obesidad y atención bariátrica. KetoAir™ mide la concentración de acetona en el aliento (BrAce) como biomarcador de cetosis, ofreciendo una alternativa no invasiva a las pruebas de sangre y orina. El dispositivo busca apoyar la gestión del peso y condiciones como la diabetes proporcionado retroalimentación en tiempo real sobre los niveles de cetosis.
아발론 글로보케어 (NASDAQ: ALBT)는 찰스 카보 박사를 과학 및 임상 자문 위원회에 임명하여 케토제닉 건강 모니터링을 위한 휴대용 호흡 측정기인 KetoAir™의 개발을 지원합니다. 카보 박사는 파운드 트랜스포메이션의 공동 창립자이자 CMO로서 비만 의학 및 비만 치료에 대한 전문 지식을 제공합니다. KetoAir™는 케토시스의 바이오마커로서 호흡 아세톤 농도(BrAce)를 측정하여 혈액 및 소변 검사에 대한 비침습적인 대안을 제공합니다. 이 장치는 케토시스 수준에 대한 실시간 피드백을 제공함으로써 체중 관리 및 당뇨병과 같은 질환을 지원하는 것을 목표로 합니다.
Avalon GloboCare (NASDAQ: ALBT) a nommé Dr. Charles Cavo à son Comité Consultatif Scientifique et Clinique afin de soutenir le développement de KetoAir™, un analyseur de souffle portable pour le suivi de la santé cétogène. Le Dr Cavo, cofondateur et CMO de Pounds Transformation, apporte son expertise dans la médecine de l'obésité et les soins bariatriques. KetoAir™ mesure la concentration d'acétone dans la respiration (BrAce) comme biomarqueur de la cétose, offrant une alternative non invasive aux tests sanguins et urinaires. L'appareil vise à soutenir la gestion du poids et des conditions comme le diabète en fournissant un retour d'information en temps réel sur les niveaux de cétose.
Avalon GloboCare (NASDAQ: ALBT) hat Dr. Charles Cavo in seinen wissenschaftlichen und klinischen Beirat berufen, um die Entwicklung von KetoAir™, einem tragbaren Atemanalysator zur Überwachung der ketogenen Gesundheit, zu unterstützen. Dr. Cavo, Mitgründer und CMO von Pounds Transformation, bringt Fachwissen in der Adipositasmedizin und bariatrischen Pflege mit. KetoAir™ misst die Atem-Acetonkonzentration (BrAce) als Biomarker für die Ketose und bietet eine nicht-invasive Alternative zu Blut- und Urintests. Das Gerät zielt darauf ab, das Gewichtsmanagement und Erkrankungen wie Diabetes zu unterstützen, indem es Echtzeit-Feedback zu den Ketose-Niveaus liefert.
- Development of innovative non-invasive ketosis monitoring device
- Strategic appointment of medical expert in obesity and bariatric medicine
- Potential market opportunity in growing GLP-1 and ketogenic diet segment
- Remote patient monitoring capabilities may create recurring revenue streams
- Product still in development phase with no current revenue generation
- Faces competition from established blood and urine ketone testing methods
Dr. Cavo’s expertise will advance the marketing and business development of KetoAir™, a handheld breathalyzer for ketogenic health
FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board.
Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epidemic in America and how it negatively affected his patient’s lives.
Dr. Cavo is a member of the board of Obesity Medicine and is board certified in Bariatric Medicine and in Obstetrics & Gynecology. He is also a fellow of the American College of Obstetricians & Gynecologists. Dr. Cavo earned his medical degree from Nova Southeastern University College of Osteopathic Medicine and completed his Obstetrics and Gynecology residency at the University of Connecticut.
“In an era where healthcare messaging increasingly focuses on prevention, KetoAir™ has the potential to be a significant tool for individuals and clinicians alike,” said David Jin, M.D., Ph.D., CEO of Avalon GloboCare. “By providing real-time insights into metabolic states, KetoAir™ is designed to assess the ketosis status of its individual user, which may assist users in managing not only weight loss but also conditions such as diabetes. Dr. Cavo’s experience will further support our efforts by helping us identify strategic development partners, while also providing valuable guidance in executing our business plan for KetoAir™.”
"I am excited to support KetoAir™ as a valuable tool in the field of obesity, where GLP-1-based diets are gaining significant relevance. Ketogenic diets play a crucial role in stimulating the natural production of the GLP-1 hormone, which may affect the regulation of appetite and blood sugar levels. By measuring Breath Acetone Concentration (BrAce) with KetoAir™, we now have a simplified and effective biomarker for determining adherence to a ketogenic diet. This may be helpful in treating chronic conditions such as diabetes and obesity. Many individuals currently monitor their ketone levels using blood and urine diagnostics However, these methods analyze the body’s storage of or excess runoff of ketones and can be easily manipulated with supplements. BrAce, a byproduct of fat metabolism, which may capture the essence of ketosis more accurately. KetoAir™ offers a non-invasive alternative delivering real-time and pain-free feedback on ketosis levels. As a valuable remote patient monitoring tool, this high-quality device is intended to empower users to track their progress, stay motivated, and make more informed decisions about their diet and exercise habits."
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is KetoAir and how does it work?
Who did Avalon GloboCare (ALBT) appoint to their Scientific Advisory Board?
What advantages does KetoAir offer over traditional ketone testing methods?
How does KetoAir relate to GLP-1 based diets?
